Background: Diabetes mellitus is a significant comorbidity of interstitial lung disease (ILD). Objectives: The aim of this study was to investigate the incidence of restrictive lung disease (RLD) and ILD in patients with prediabetes and type 2 diabetes (T2D). Methods: Forty-eight nondiabetics, 68 patients with prediabetes, 29 newly diagnosed T2D, and 110 patients with long-term T2D were examined for metabolic control, diabetes-related complications, breathlessness, and lung function. Five participants with T2D, breathlessness, and RLD underwent multidetector computed tomography (MDCT) and a Six-Minute Walk Test (6MWT). Lung tissue from 4 patients without diabetes and from 3 patients with T2D was histologically examined for presence of pulmonary fibrosis. Results: Breathlessness in combination with RLD was significantly increased in patients with prediabetes and T2D (p < 0.01). RLD was found in 9% of patients with prediabetes, in 20% of patients with newly diagnosed T2D, and in 27% of patients with long-term T2D. Thus, patients with long-term T2D had an increased risk of RLD (OR 5.82 [95% CI 1.71–20.5], p < 0.01). RLD was significantly associated with glucose metabolism and albuminuria (p < 0.01); furthermore, presence of nephropathy increased the risk of RLD (OR 8.57 [95% CI 3.4–21.9], p < 0.01) compared to nondiabetics. MDCT revealed ILD in 4 patients, the 6MWT correlated with the extent of ILD, and histological analysis showed fibrosing ILD in patients with T2D. Conclusions: This study demonstrates increased breathlessness and a high prevalence of RLD in patients with T2D, indicating an association between diabetes and fibrosing ILD.

Keywords:
Fibrosing interstitial lung disease, Type 2 diabetes, Albuminuria, Diabetes-related complications
1.
Berliner D, Schneider N, Welte T, Bauersachs J: The differential diagnosis of dyspnea. Dtsch Arztebl Int 2016; 113: 834–845.
2.
Frese T, Sobeck C, Herrmann K, Sandholzer H: Dyspnea as the reason for encounter in general practice. J Clin Med Res 2011; 3: 239–246.
3.
Kornum JB, Christensen S, Grijota M, Pedersen L, Wogelius P, Beiderbeck A, Sørensen HT: The incidence of interstitial lung disease 1995–2005: a Danish nationwide population-based study. BMC Pulm Med 2008; 8: 24.
4.
Maher TM, Wells AU, Laurent GJ: Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 2007; 30: 835–839.
5.
Richeldi L, Collard HR, Jones MG: Idiopathic pulmonary fibrosis. Lancet 2017; 389: 1941–1952.
6.
Yan Z, Kui Z, Ping Z: Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis. Autoimmun Rev 2014; 13: 1020–1025.
7.
Sandler M: Is the lung a “target organ” in diabetes mellitus? Arch Intern Med 1990; 150: 1385–1388.
8.
Hyldgaard C, Hilberg O, Muller A, Bendstrup E: A cohort study of interstitial lung diseases in central Denmark. Respir Med 2014; 108: 793–799.
9.
Benbassat CA, Stern E, Kramer M, Lebzelter J, Blum I, Fink G: Pulmonary function in patients with diabetes mellitus. Am J Med Sci 2001; 322: 127–132.
10.
Yang J, Xue Q, Miao L, Cai L: Pulmonary fibrosis: a possible diabetic complication. Diabetes Metab Res Rev 2011; 27: 311–317.
11.
Klein OL, Krishnan JA, Glick S, Smith LJ: Systematic review of the association between lung function and type 2 diabetes mellitus. Diabet Med 2010; 27: 977–987.
12.
Kim YJ, Park JW, Kyung SY, Lee SP, Chung MP, Kim YH, Lee JH, Kim YC, Ryu JS, Lee HL, Park CS, Uh ST, Lee YC, Kim KH, Chun YJ, Park YB, Kim DS, Jegal Y, Lee JH, Park MS, Jeong SH: Clinical characteristics of idiopathic pulmonary fibrosis patients with diabetes mellitus: the national survey in Korea from 2003 to 2007. J Korean Med Sci 2012; 27: 756–760.
13.
Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, Heussel CP, Warth A, Kolb M, Herth FJ: Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS One 2016; 11:e0151425.
14.
Enomoto T, Usuki J, Azuma A, Nakagawa T, Kudoh S: Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest 2003; 123: 2007–2011.
15.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–612.
16.
Kishaba T, Nagano H, Nei Y, Yamashiro S: Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status. J Thorac Dis 2016; 8: 1112–1120.
17.
Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J; ERS Global Lung Function Initiative: Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J 2012; 40: 1324–1343.
18.
Robinson PD, Latzin P, Verbanck S, Hall GL, Horsley A, Gappa M, Thamrin C, Arets HG, Aurora P, Fuchs SI, King GG, Lum S, Macleod K, Paiva M, Pillow JJ, Ranganathan S, Ratjen F, Singer F, Sonnappa S, Stocks J, Subbarao P, Thompson BR, Gustafsson PM: Consensus statement for inert gas washout measurement using multiple- and single-breath tests. Eur Respir J 2013; 41: 507–522.
19.
Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J: Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948–968.
20.
Brack T, Jubran A, Tobin MJ: Dyspnea and decreased variability of breathing in patients with restrictive lung disease. Am J Respir Crit Care Med 2002; 165: 1260–1264.
21.
Kopf S, Oikonomou D, Zdunek D, von Eynatten M, Hess G, Nawroth PP, Bierhaus A, Humpert PM: Urinary n-acetyl-beta-d-glucosaminidase excretion: an indicator of neuropathy in type 2 diabetes. Exp Clin Endocrinol Diabetes 2013; 121: 601–606.
22.
Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH: A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 150–154.
23.
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
24.
Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D; ATS/ERS Committee on Idiopathic Interstitial Pneumonias: An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733–748.
25.
Enright PL, Sherrill DL: Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 1998; 158: 1384–1387.
26.
Wilson RC, Jones PW: A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnoea during exercise. Clin Sci (Lond) 1989; 76: 277–282.
27.
American Diabetes Association: 10. Microvascular complications and foot care. Diabetes Care 2017; 40(suppl 1):S88–S98.
28.
IDF Clinical Guidelines Task Force: Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006; 23: 579–593.
29.
Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Kato K, Kataoka K, Ogawa T, Watanabe F, Arizono S: A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J 2010; 36: 1067–1072.
30.
Kim MK, Baek KH, Song KH, Kwon HS, Lee JM, Kang MI, Yoon KH, Cha BY, Son HY, Lee KW: Exercise treadmill test in detecting asymptomatic coronary artery disease in type 2 diabetes mellitus. Diabetes Metab J 2011; 35: 34–40.
31.
Scarlata S, Costanzo L, Giua R, Pedone C, Incalzi RA: Diagnosis and prognostic value of restrictive ventilatory disorders in the elderly: a systematic review of the literature. Exp Gerontol 2012; 47: 281–289.
32.
Davis WA, Knuiman M, Kendall P, Grange V, Davis TM; Fremantle Diabetes Study: Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2004; 27: 752–757.
33.
Davis TM, Knuiman M, Kendall P, Vu H, Davis WA: Reduced pulmonary function and its associations in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Res Clin Pract 2000; 50: 153–159.
34.
Teeter JG, Riese RJ: Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study: response to Yeh et al. Diabetes Care 2008; 31:e82.
35.
Van den Borst B, Gosker HR, Zeegers MP, Schols AM: Pulmonary function in diabetes: a metaanalysis. Chest 2010; 138: 393–406.
36.
Papinska AM, Soto M, Meeks CJ, Rodgers KE: Long-term administration of angiotensin (1–7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes (db/db) by reducing oxidative stress, inflammation and pathological remodeling. Pharmacol Res 2016; 107: 372–380.
37.
Hu Y, Ma Z, Guo Z, Zhao F, Wang Y, Cai L, Yang J: Type 1 diabetes mellitus is an independent risk factor for pulmonary fibrosis. Cell Biochem Biophys 2014; 70: 1385–1391.
38.
Kumar V, Fleming T, Terjung S, Gorzelanny C, Gebhardt C, Agrawal R, Mall MA, Ranzinger J, Zeier M, Madhusudhan T, Ranjan S, Isermann B, Liesz A, Deshpande D, Haring HU, Biswas SK, Reynolds PR, Hammes HP, Peperkok R, Angel P, Herzig S, Nawroth PP: Homeostatic nuclear RAGE-ATM interaction is essential for efficient DNA repair. Nucleic Acids Res 2017; 45: 10595–10613.
39.
Oh IH, Park JH, Lee CH, Park JS: The association of normal range glycated hemoglobin with restrictive lung pattern in the general population. PLoS One 2015; 10:e0117725.
40.
Jagadapillai R, Rane MJ, Lin X, Roberts AM, Hoyle GW, Cai L, Gozal E: Diabetic microvascular disease and pulmonary fibrosis: the contribution of platelets and systemic inflammation. Int J Mol Sci 2016; 17:E1853.
41.
King TE Jr, Pardo A, Selman M: Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949–1961.
42.
Ikezoe K, Handa T, Tanizawa K, Yokoi H, Kubo T, Aihara K, Sokai A, Nakatsuka Y, Hashimoto S, Uemasu K, Sato S, Muro S, Nagai S, Yanagita M, Chin K, Hirai T, Taguchi Y, Mishima M: Chronic kidney disease predicts survival in patients with idiopathic pulmonary fibrosis. Respiration 2017; 94: 346–354.
43.
Chung JH, Richards JC, Koelsch TL, MacMahon H, Lynch DA: Screening for lung cancer: incidental pulmonary parenchymal findings. AJR Am J Roentgenol 2018; 210: 503–513.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.